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Abstract
Background: Gestational diabetes (GDM) is a more common problem in India than in many other parts of the
world but it is not known whether this is due to unique environmental factors or a unique genetic background. To
address this question we examined whether the same genetic variants associated with GDM and Type 2 Diabetes
(T2D) in Caucasians also were associated with GDM in North Indian women.
Methods: Five thousand one hundred pregnant women of gestational age 24–28 weeks from Punjab were studied
by a 75 g oral glucose tolerance test (OGTT). GDM was diagnosed by both WHO1999 and 2013 criteria. 79 single
nucleotide polymorphisms (SNPs) previously associated with T2D and glycemic traits (12 of them also with GDM)
and 6 SNPs from previous T2D associations based on Indian population (some also with European) were genotyped
on a Sequenom platform or using Taqman assays in DNA from 4018 women.
Results: In support of previous findings in Caucasian GDM, SNPs at KCJN11 and GRB14 loci were nominally
associated with GDM1999 risk in Indian women (both p = 0.02). Notably, T2D risk alleles of the variant rs1552224
near CENTD2, rs11708067 in ADCY5 and rs11605924 in CRY2 genes associated with protection from GDM regardless
of criteria applied (p < 0.025). SNPs rs7607980 near COBLL1 (p = 0.0001), rs13389219 near GRB14 (p = 0.026) and
rs10423928 in the GIPR gene (p = 0.012) as well as the genetic risk score (GRS) for these previously shown insulin
resistance loci here associated with insulin resistance defined by HOMA2-IR and showed a trend towards GDM. GRS
comprised of 3 insulin secretion loci here associated with insulin secretion but not GDM.
Conclusions: GDM in women from Punjab in Northern India shows a genetic component, seemingly driven by
insulin resistance and secretion and partly shared with GDM in other parts of the world. Most previous T2D loci
discovered in European studies did not associate with GDM in North India, indicative of different genetic etiology
or alternately, differences in the linkage disequilibrium (LD) structure between populations in which the associated
SNPs were identified and Northern Indian women. Interestingly some T2D risk variants were in fact indicative of
being protective for GDM in these Indian women.
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Background
Gestational Diabetes Mellitus (GDM) has been officially
defined as “carbohydrate intolerance” of variable severity
with onset or first recognition during pregnancy [1–3]
irrespective of treatment and whether or not the condi-
tion persists after pregnancy. GDM represents almost
90% of all pregnancies complicated by diabetes [4]. The
prevalence of GDM is rapidly increasing, ranging from 2
to 14% depending upon diagnostic criteria [5, 6]. In a
study of South Indian women, GDM prevalence varied
between 12 and 21% [7] while another study of North
Indian women reported a prevalence of 10% using
WHO criteria [8]. The hallmark of GDM is increased in-
sulin resistance accompanied by decreased compensa-
tory insulin secretory response. Type 2 diabetes (T2D) is
also caused by increased insulin resistance and decreased
insulin secretion to compensate for the former. Thus,
both T2D and GDM share the same pathophysiology
which is influenced by similar risk factors like high
body mass index (BMI), history of abnormal glucose
intolerance, family history of diabetes, age, and ethni-
city [9–11].
A family history of both T2D and GDM is known to
increase GDM risk, indicative of a common genetic
component underlying both T2D and GDM [12, 13]. Till
date, more than 120 T2D risk loci have been confirmed
to be associated with T2D [14]. A large proportion of
them have also shown association with GDM. T2D risk
variants at the MTNR1B, FTO, TLE1, G6PC2, GCKR,
TCF7L2, ADCY5, CDKAL1, TCF2, HNF1B, PPARG,
KCNJ11, SLC30A8 loci have previously been associated
with GDM in European populations [15–18] whereas
variants in the CDKAL1, CDKN2A/2B, MTNR1B and
KCNQ1 loci were associated with GDM in Korean
women [19, 20].
Some genetic variants are more unique to Indian T2D
patients e.g. the SGCG (rs9552911) and TMEM163
(rs998451) variants [21–25]. However, genetic studies of
GDM in India are scarce. The SNPs rs7754840 and
rs7756992 in the CDKAL1 gene were associated with
GDM in South Indian women [26], while variants in the
HMG20A (rs7178572) and HNF4A (rs4812829) genes
were associated with both GDM and T2D [27]. The aim
of the present study was to investigate whether a panel
of known variants previously associated with GDM and
T2D in Indian and European populations are associated
with GDM in Punjabi women.
Methods
Study population and phenotyping
Five thousand one hundred pregnant women were
recruited by applying a multistage random screening in
the State of Punjab in North India for GDM. Pregnant
women at gestational week 24–28 were randomly
selected and recruited [8, 28]. This was part of a WDF
supported project titled “Gestational diabetes in Punjab”
with the goal to create and implement sustainable
awareness, education, screening, intervention and treat-
ment capacities of diabetes in pregnancy (GDM) within
the public and private health care system, as well as in
the general population in Punjab. The team included a
chief research coordinator, an assistant coordinator, doc-
tors, nurses, lab technicians from all selected sites both
in private hospitals and public healthcare system. Ap-
proval for screening was obtained from DRME, Chandi-
garh, India. The recruitment sites included Recruitment
sites:, Deep Hospital, Model Town, Ludhiana as the epi-
center, Shri Rama Charitable Hospital, Ludhiana, Chawla
Hospital, Ludhiana, Iqbal Hospital, Ludhiana, Govern-
ment Medical Colleges and Hospital, Patiala, Amritsar
and Faridkot, PHC Verka, Amritsar, Health Centre
Bhadsoan, Patiala, Health Centre Faridkot. The project
was approved by Independent ethics committee, Lud-
hiana in 2009. The ethics committee is registered with
Office of Drugs Controller General (India) Directorate
General of Health Services with Registration no. ECR/
525/Inst/PB/2014.
Information was obtained on age, BMI, family history
of diabetes, diet, habitat (urban or rural), education and
religion. All information material and written consent
forms were provided in 3 languages (Hindi, Punjabi &
English) and duly signed by the participants. The study
protocol was approved by local Ethical Committees.
Glucose was measured in venous plasma samples at fast-
ing and at 2 h after a 75 g glucose challenge using gluc-
ometers (Accucheck-Roche Diagnostics). Fasting insulin
concentrations were determined with ELISA (Diametra,
Milan, Italy; intra- and inter-assay variation of < 5.0 and
< 10.0%, respectively). The homeostatic model assess-
ment (HOMA2) was used to quantify insulin resistance
(HOMA2-IR) and beta-cell function (HOMA2-B) from
fasting insulin and glucose values using the HOMA2 cal-
culator v2.2.3 (http://https://www.dtu.ox.ac.uk/homacal-
culator/) [29]. GDM was diagnosed according to the
WHO1999 (FPG ≥7.0 mmol/l and/or 2-h glucose
≥7.8 mmol/l) and the adapted WHO2013 (FPG ≥5.1
and/or 2-h glucose ≥8.5 mmol/l) criteria (ref ). The clin-
ical characteristics of subjects are shown in Table 1.
Genotyping
DNA was extracted from frozen and stored buffy coats
using (QIAGEN Autopure LS kits. Six SNPs previously
associated with GDM or T2D in India [21, 22, 26, 27, 30]
(Additional file 2: Table S1) and 79 SNPs previously asso-
ciated with T2D in Europe and elsewhere from GWAS
studies up to 2012 (some of these also with GDM risk
from candidate gene studies in GDM populations) were
genotyped in the present study (Additional file 2: Table
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S1) [14] on a Sequenom Mass ARRAY Platform (Seque-
nom San Diego, CA, USA) PLEX using MALDI-TOF
mass spectrometer [31] or Taqman allelic discrimination
assays using an ABI Prism 7900 sequence detection sys-
tem (Applied Biosystems, Foster City, CA, USA). Geno-
typing was performed at the Lund University Diabetes
Centre, Sweden after obtaining permission from ICMR
(dated 21 october 2010 and Office of Drugs Controller
General (India)(dated 14/12/2010).
Replication genotyping of 6% of the samples showed >
98% concordance. rs6467136, and rs7202877 had a
Hardy-Weinberg equilibrium (HWE) p-value of < 0.001
in unaffected women based on WHO1999 criteria and <
0.05 in unaffected women based on WHO2013 criteria
and were hence removed from the analysis.
Statistical analyses
Association of selected SNPs with risk of GDM was
assessed by logistic regression analysis adjusted for
maternal age and BMI and results presented as ORs with
95% confidence intervals (CI). We also tested for associ-
ations with fasting and 2-h glucose values as well as with
fasting insulin and HOMA2-B and HOMA2-IR (Add-
itional file 2: Table S1) using linear regression analysis
with maternal age and BMI as covariates. Individuals
with missing data were excluded. Data were logarithmic-
ally transformed before analysis. The power to detect as-
sociation with GDM2013 including 1386 GDM women
and 2632 controls at p < 0.0006 (0.05/79) (after Bonfer-
roni correction) for a SNP allele frequency of 0.3 and ef-
fect size 1.3 was 0.97, which decreased to 0.64 for
effect size 1.2 under an additive model. For
GDM1999, with 346 GDM and 3672 controls, the
corresponding figures were 0.39 and 0.12 respect-
ively. For association with quantitative glucose traits,
power to detect association was 1 at alpha 0.05 for
and allele frequency of 0.3 [32, 33]. A p-value of
≤0.05 was considered statistically significant on
account of the current analyses being replication of
previously published associations.
Genetic risk scores for insulin secretion (HOMA-2B)
and insulin resistance (HOMA-2IR) were calculated
using SNPs previously associated with insulin secretion
and insulin resistance. SNPs were assessed for linkage
disequilibrium (LD) and for those in high LD (r2), only
one representative SNP was retained. Individual scores
were calculated based on number of risk alleles weighed
by their effect sizes reported in previous GWAS studies
and logistic regression was performed against normal-
ized measures of insulin secretion and insulin resistance.
All calculations were implemented in STATA, plink
1.09 and SPSS v22.0.
Results
Among the 4018 genotyped women, applying the
WHO2013 criteria resulted in a total of 1386 women
with GDM (34.5%) whereas the number was reduced to
346 (8.6%) when WHO1999 criteria were used. Notably,
only 283 (7.0%) women were diagnosed using both
GDM 2013 and GDM 1999 criteria (Additional file 1:
Figure S1) [34]. This is concordant with our previously
published reports on the larger subset of the same popu-
lation comprising 5100 women [28]. HOMA2-B was
lower in GDM women defined by both criteria com-
pared to pregnant normal glucose tolerant women
(PNGT). HOMA2-IR was also higher in women with
GDM2013 who thereby were more insulin resistant than
PNGT (Table 1).
SNPs previously associated with GDM/T2D in India
None of the 8 SNPs previously associated with GDM or
T2D in Indian populations was here associated with
GDM (Table 2). However, analysis for association with
GDM1999 or GDM 2013 against controls who did not
satisfy either criterion revealed the nominal association
of rs7756992 in CDKAL1 while rs689 in INS showed a
trend towards association with GDM2013 (Table 3).
Table 1 Study population characteristics
GDM1999 Controls GDM2013 Controls
N Mean ±SD N Mean ±SD N Mean ±SD N Mean ±SD N Mean ±SD
Age (years) 4018 21.41 3.40 346 21.11 3.59 3672 21.44 3.38 1386 21.68 3.5 2632 21.27 3.34
BMI 4018 24.11 4.34 346 24.28 4.71 3672 24.09 4.30 1386 24.36 4.48 2632 23.97 4.25
Fasting plasma glucose (mmol/l) 4018 4.81 0.76 346 5.53 1.32 3672 4.74 0.65 1386 5.51 0.69 2632 4.44 0.49
Plasma insulin (pmol) 4018 54.25 61.86 346 46.73 42.24 3672 54.96 63.35 1386 52.74 54.44 2632 55.05 65.43
2 h glucose (venous, mmol/l) 4018 6.20 1.37 346 9.15 1.83 3672 5.93 0.92 1386 6.85 1.70 2632 5.86 1.00
homa2_b with steady state
glucose and insulin values
3680 104.02 55.71 346 78.01 37.56 3672 106.36 56.49 1386 77.37 38.02 2632 117.92 58.36
homa2_ir with steady state
glucose and insulin values
3680 0.97 0.74 346 0.96 0.73 3672 0.97 0.74 1386 1.02 0.79 2632 0.95 0.71
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Previously reported GDM risk loci
Out of 12 selected previously reported GDM risk loci,
the T allele of the missense SNP rs5219 in the KCNJ11
gene was nominally associated with GDM1999 (p =
0.019) (Table 4). Contrary to previous reports, the risk
allele A of SNP rs11708067 in the ADCY5 gene showed
reduced risk for GDM defined by 2013 (p = 0.037) (Table 4)
but not by 1999 criteria. The SNP rs2796441 in the TLE1
gene was associated with decreased insulin secretion (p =
0.013) (Additional file 2: Table S2). The rs13266634 at
SLC30A8 locus associated with GDM1999 while SNPs
rs5219 in KCNJ11 and rs11708067 in ADCY5 associated
with GDM2013 nominally when controls satisfying neither
GDM diagnosis criteria were considered (Table 3).
Previously reported T2D loci
The risk allele C of SNP rs13389219 in the GRB14 gene
was associated with GDM1999 (p = 0.022) (Table 5) but
not with GDM2013 (p = 0.058) (Table 5). The T2D risk al-
lele T of SNP rs11920090 in the intron of the SLC2A2
gene was associated with GDM2013 (p = 0.030) (Table 5).
Surprisingly, the T2D risk allele A of SNP rs11605924
in the CRY2 gene was associated with reduced risk of
GDM1999 (p = 0.025) (Table 5). The same variant asso-
ciated with GDM1999 in a sensitivity analysis when con-
trols meeting neither GDM diagnosis criteria were
considered (Table 3). In support of this, the same allele
was also associated with lower 2-h glucose levels (p =
0.038) (Additional file 2: Table S3).
Table 2 Association of previously reported GDM and T2D loci from Indian population based studies with risk of GDM according to
both criteria











rs998451 A 2 TMEM163 intron 0.987 0.795 1.224 0.902 0.959 0.843 1.09 0.518 3882
rs1799999 A 7 PPP1R3A missense 0.862 0.728 1.02 0.083 0.997 0.905 1.098 0.953 3890
rs689 A 11 INS 5’UTR 1.077 0.879 1.319 0.474 1.033 0.914 1.167 0.603 3903
rs9552911 A 13 SGCG intron 1.057 0.83 1.347 0.653 1.017 0.875 1.183 0.824 3890
rs4812829 A 20 HNF4A intron 1.04 0.871 1.24 0.667 0.988 0.89 1.096 0.814 3801
rs7178572 G 15 HMG20A intron 0.988 0.832 1.173 0.891 1.017 0.921 1.122 0.743 3541
rs7756992 G 6 CDKAL 1 intron 0.91 0.75 1.1 0.34 0.97 0.87 1.08 0.64 3686
rs7754840 C 6 CDKAL1 intron 0.87 0.72 1.06 0.17 0.96 0.86 1.07 0.51 3721
EA effect allele, OR_WHO1999 odds ratio based on WHO1999 criteria, OR_WHO2013 Odds ratio based on WHO2013 criteria, CI confidence interval
Table 3 Association of previously reported GDM loci with risk of GDM according to both criteria
SNP EA Chr Gene/nearest
gene
Location WHO 1999 WHO 2013 n
OR CI(lower) CI(upper) p-value OR CI(lower) CI(upper) p-value
rs9939609 A 16 FTO intron 1.04 0.86 1.26 0.67 0.98 0.88 1.10 0.83 3120
rs2796441 G 9 TLE 1 intergenic 0.99 0.84 1.16 0.92 1.07 0.97 1.17 0.15 3905
rs560887 C 2 G6PC2/ABCB11 intron 1.18 0.92 1.52 0.19 1.11 0.96 1.28 0.13 3910
rs11708067 A 3 ADCY5 intron 0.98 0.81 1.18 0.86 0.88 0.79 0.99 0.037 3877
rs1111875 C 10 HHEX intergenic 0.90 0.77 1.06 0.22 1.05 0.96 1.16 0.24 3901
rs10811661 T 9 CDKN2A/2B intergenic 0.99 0.77 1.26 0.93 1.08 0.94 1.25 0.23 3890
rs4402960 T 3 IGF2BP2 intron 1.02 0.87 1.20 0.77 0.95 0.86 1.04 0.29 3750
rs13266634 C 8 SLC30A8 coding-missense 0.96 0.79 1.17 0.75 0.97 0.87 1.08 0.61 3898
rs7903146 T 10 TCF7L2 Intronic/promoter 1.13 0.95 1.35 0.14 1.01 0.916 1.12 0.76 3543
rs10830963 G 11 MTNR1B intron 0.89 0.75 1.05 0.20 0.98 0.89 1.08 0.69 3714
rs1801282 C 3 PPARG Coding-missense 0.86 0.89 1.12 0.22 0.99 0.93 1.08 0.21 3652
rs10010131 G 4 WFS1 intron 1.13 0.95 1.36 0.16 0.99 0.90 1.10 0.99 3843
rs5219 T 11 KCNJ11 coding-missense 1.21 1.03 1.42 0.019 1.00 0.90 1.10 0.99 3595
EA effect allele, OR_WHO1999 odds ratio based on WHO1999 criteria, OR_WHO2013 Odds ratio based on WHO2013 criteria, CI confidence interval
significant p values where p < 0.05 are indicated in bold
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Table 4 Association of previously reported T2D loci with risk of GDM according to both criteria
SNP EA Chr Gene/nearest
gene
Location WHO 1999 WHO 2013 n
OR CI(lower) CI(upper) p-value OR CI(lower) CI(upper) p-value
rs2296172 G 1 MACF1 coding-missense 0.92 0.71 1.20 0.56 1.04 0.89 1.21 0.58 3847
rs340874 C 1 PROX1 intergenic 0.94 0.80 1.11 0.52 0.96 0.87 1.06 0.47 3709
rs7578597 T 2 THADA coding-missense 0.90 0.72 1.12 0.37 0.92 0.80 1.06 0.27 3710
rs243088 T 2 BCL 11A intergenic 1.10 0.94 1.29 0.22 1.07 0.97 1.18 0.15 3717
rs7593730 T 2 RBMS1/ITGB6 intronic 1.01 0.84 1.22 0.83 0.99 0.88 1.11 0.93 3906
rs7607980 C 2 COBLL1 coding-missense 0.95 0.73 1.24 0.75 0.95 0.81 1.11 0.52 3885
rs13389219 C 2 GRB14 intergenic 1.25 1.03 1.52 0.022 1.11 0.99 1.23 0.058 3829
rs7578326 A 2 KIAA1486/IRS1 intron of uncharacterized
LOC646736
0.97 0.80 1.18 0.78 0.98 0.87 1.10 0.79 3600
rs2943641 C 2 IRS1 intergenic 0.92 0.76 1.12 0.43 0.97 0.87 1.09 0.67 3643
rs4675095 A 2 IRS1 intron 1.11 0.87 1.42 0.39 1.04 0.90 1.19 0.58 3817
rs831571 C 3 PSMD6 intergenic 1.02 0.84 1.25 0.77 0.93 0.83 1.05 0.26 3726
rs4607103 C 3 ADAMTS9-AS2 intron 1.14 0.98 1.33 0.08 1.00 0.91 1.09 0.97 3884
rs11920090 T 3 SLC2A2 intron 1.19 0.93 1.51 0.16 1.16 1.01 1.33 0.03 3606
rs6815464 C 4 MAEA intron 1.04 0.83 1.30 0.71 1.03 0.90 1.18 0.64 3722
rs459193 G 5 ANKRD55 intergenic 0.99 0.84 1.16 0.90 1.07 0.97 1.18 0.16 3884
rs4457053 G 5 ZBED3 intron of ZBED3-AS1 1.05 0.86 1.29 0.57 0.95 0.84 1.07 0.45 3579
rs9470794 C 6 ZFAND3 intron 1.07 0.85 1.35 0.51 1.05 0.91 1.21 0.48 3608
rs17168486 T 7 DGKB intergenic 0.99 0.83 1.17 0.92 0.97 0.88 1.07 0.62 3855
rs2191349 T 7 DGKB/TMEM195 intergenic 1.04 0.88 1.22 0.62 1.00 0.91 1.10 0.95 3903
rs864745 T 7 JAZF1 intron 0.98 0.83 1.16 0.87 1.02 0.92 1.13 0.68 3876
rs4607517 A 7 GCK intergenic 1.04 0.82 1.32 0.70 1.01 0.88 1.16 0.86 3903
rs17133918 C 7 GRB10 intron 1.03 0.87 1.23 0.67 0.97 0.88 1.08 0.65 3907
rs933360 A 7 GRB10 intron 1.03 0.87 1.22 0.70 1.03 0.93 1.14 0.54 3905
rs6943153 C 7 GRB10 intron 0.86 0.73 1.03 0.11 0.95 0.86 1.05 0.36 3602
rs516946 C 8 ANK1 intron 1.01 0.82 1.23 0.91 1.09 0.97 1.23 0.13 3922
rs896854 T 8 TP53INP1 intron 0.97 0.83 1.14 0.75 0.97 0.88 1.06 0.57 3903
rs7034200 A 9 GLIS3 intron 0.98 0.83 1.15 0.84 1.03 0.93 1.13 0.52 3868
rs13292136 C 9 TLE4 (CHCHD9) intergenic 0.94 0.75 1.18 0.62 0.98 0.86 1.12 0.79 3706
rs12571751 A 10 ZMIZ1 intron 0.86 0.73 1.01 0.07 0.96 0.87 1.06 0.49 3601
rs553668 A 10 ADRA2A UTR-3 1.17 0.99 1.39 0.06 1.07 0.97 1.19 0.15 3666
rs10885122 G 10 ADRA2A intergenic 1.03 0.84 1.27 0.75 1.05 0.93 1.18 0.42 3683
rs163184 G 11 KCNQ1 intron 0.90 0.76 1.07 0.23 1.00 0.90 1.10 0.98 3713
rs2237895 C 11 KCNQ1 intron 0.96 0.81 1.13 0.66 1.01 0.92 1.11 0.79 3682
rs11605924 A 11 CRY2 intron 0.84 0.72 0.97 0.025 1.00 0.92 1.10 0.85 3909
rs7944584 A 11 MADD intron 0.91 0.74 1.13 0.41 1.09 0.96 1.23 0.15 3553
rs174550 T 11 FADS1 intron 0.94 0.76 1.17 0.62 0.96 0.85 1.09 0.56 3908
rs1552224 A 11 CENTD2 intergenic 0.92 0.75 1.13 0.45 0.81 0.72 0.92 0.001 3911
rs11063069 G 12 CCND2 intergenic 0.99 0.80 1.23 0.98 1.04 0.91 1.19 0.52 3671
rs10842994 C 12 KLHDC5 intergenic 1.13 0.89 1.44 0.28 0.97 0.84 1.11 0.67 3906
rs1153188 A 12 DCD intergenic 1.15 0.93 1.42 0.19 1.01 0.89 1.14 0.82 3912
rs1531343 C 12 HMGA2 intron of pseudogene 0.83 0.67 1.03 0.09 0.90 0.80 1.02 0.10 3915
rs7961581 C 12 TSPAN8,LGR5 intergenic 0.91 0.77 1.08 0.31 1.02 0.92 1.13 0.61 3703
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The risk allele A of SNP rs1552224 in the CENTD2
locus was associated with decreased risk of GDM2013
(p = 0.001) (Table 5).
Association with insulin secretion and insulin resistance
Twelve SNPs previously associated with insulin secretion
were here tested for association with HOMA2-B. The
T2D risk allele A of rs11071657 at the FAM148B locus
was nominally associated with increased insulin secretion
(p = 0.044) (Table 6). A GRS comprising of 3 previously
reported insulin secretion loci with the lowest p-values for
insulin secretion in the present study associated with insu-
lin secretion in the present study (p = 0.008, beta = 0.25,
SE = 0.098). GRS for insulin secretion did not associate
with either GDM2013 (p = 0.15, beta = − 0.06, SE = 0.045)
or GDM1999 (p = 0.73, beta = − 0.009, SE = 0.026).
Of 6 SNPs previously associated with measures of
insulin resistance, 3 SNPs here associated with
HOMA2-IR. The C allele of rs7607980 in the COBLL1
gene was associated with decreased HOMA2-IR (p =
0.0001). The C allele of rs13389219 near GRB14 (p =
0.026) and A allele of rs10423928 in the intron of the
GIPR gene (p = 0.012) showed worse insulin resistance
(increased HOMA2-IR; Table 7). Genetic risk scores
(GRS) calculated based on the 3 SNPs associated with
insulin resistance showed an increase of insulin resist-
ance by 0.07 (SE = 0.145, p = 0.006) per allele. GRS for
insulin resistance showed a trend towards GDM2013
Table 5 Sensitivity analysis for association of selected risk variants with GDM risk
SNP EA Chr Gene/
nearest
gene
Location WHO 1999 WHO 2013 n
OR CI(lower) CI(upper) p-value n OR CI(lower) CI(upper) p-value
rs13266634a T 8 SLC30A8 coding-missense 1.24 1.01 1.53 0.037 2834 1.049 0.91 1.21 0.50 3837
rs11605924 A 11 CRY2 intron 0.84 0.71 0.99 0.038 2833 1.005 0.91 1.10 0.91 3848
rs35767 T 12 IGF1 nearGene-5 1.26 1.00 1.60 0.054 2837 1.15 0.98 1.33 0.07 3848
rs5219a T 11 KCNJ11 coding -missense 1.18 1.00 1.40 0.059 2605 1.00 0.91 1.11 0.91 3539
rs11708067a G 3 ADCY5 intron 1.11 0.86 1.44 0.42 2810 1.25 1.09 1.45 0.002 3816
rs689a A 11 INS Promoter/intron 0.91 0.64 1.29 0.60 2835 0.81 0.65 1.00 0.054 3842
rs8108269 G 19 GIPR intergenic 1.14 0.94 1.36 0.17 2568 1.12 0.99 1.25 0.059 3449
rs7756992a G 6 CDKAL1 intron 0.96 0.76 1.19 0.69 2670 2.80 1.00 7.87 0.049 3626
aindicates loci previously associated with GDM / T2D in India or GDM in studies based on the European population
Logistic regression was performed on GDM cases diagnosed according to WHO1999 and WHO2013 criteria against controls who had no GDM diagnosis using
either criteria
significant p values where p < 0.05 are indicated in bold
Table 4 Association of previously reported T2D loci with risk of GDM according to both criteria (Continued)
SNP EA Chr Gene/nearest
gene
Location WHO 1999 WHO 2013 n
OR CI(lower) CI(upper) p-value OR CI(lower) CI(upper) p-value
rs7957197 T 12 OASL/TCF1/HNF1A intron of QASL 0.87 0.65 1.17 0.37 1.00 0.83 1.21 0.96 3924
rs17271305 G 15 VPS13C intron 1.02 0.86 1.20 0.81 0.92 0.83 1.02 0.15 3825
rs11071657 A 15 FAM148B intergenic 1.03 0.87 1.22 0.72 0.92 0.83 1.02 0.13 3897
rs7177055 A 15 HMG20A intergenic 1.00 0.85 1.17 0.99 0.98 0.89 1.08 0.74 3907
rs35767 G 12 IGF1 nearGene-5 0.88 0.91 1.10 0.19 0.93 0.94 1.06 0.21 3910
rs11634397 G 15 ZFAND6 intergenic 0.89 0.76 1.04 0.16 0.96 0.87 1.06 0.47 3910
rs8042680 A 15 PRC1 intron 0.89 0.76 1.04 0.16 0.99 0.90 1.10 0.95 3887
rs8090011 G 18 LAMA1 intron 0.95 0.81 1.11 0.57 0.93 0.84 1.02 0.13 3911
rs10401969 C 19 SUGP1 intron 0.96 0.72 1.27 0.79 0.86 0.72 1.01 0.07 3605
rs8108269 G 19 GIPR intergenic 1.02 0.85 1.23 0.77 1.07 0.96 1.19 0.16 3508
rs10423928 A 19 GIPR intron 0.85 0.67 1.08 0.20 1.06 0.93 1.20 0.37 3911
rs6017317 G 20 FITM2-R3HDML-
HNF4A
intergenic 0.96 0.81 1.13 0.64 0.98 0.89 1.08 0.72 3758
rs5945326 A X DUSP9 intergenic 0.95 0.81 1.12 0.58 1.01 0.92 1.12 0.74 3589
EA effect allele, OR_WHO1999 odds ratio based on WHO1999 criteria, OR_WHO2013 Odds ratio based on WHO2013 criteria, CI confidence interval
significant p values where p < 0.05 are indicated in bold
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(p = 0.065, beta = 0.076, SE = 0.04) but not GDM1999
(p = 0.14, beta = 0.023, SE = 0.025).
Discussion
In this large study, we investigated the genetic basis
of gestational diabetes mellitus in Punjabi Indian
women [15, 16, 19, 27].
Surprisingly, the genetic variants in the HMG20A and
HNF4A genes which previously have been associated
with risk of T2D and GDM in South India [27] were not
associated with GDM or T2D in Punjabi pregnant
women. This could be due to differences in allele fre-
quencies between the North and South Indian popula-
tions, which are ethnically quite distinctive populations
[35]. The Punjabi Indian population belongs to the “An-
cestral North Indians” group and shares genetic similar-
ities with populations from Middle East, Central Asia
and to some degree Europe whereas the South Indian
population genetically belongs to the distinct “Ancestral
South Indian” group [35]. Notably the CDKAL1 variant
associated with GDM only when a sensitivity analysis
was performed using controls that had no GDM diagno-
sis using either GDM1999 or GDM2013 criteria, thus
replicating a previous association.
Neither did we observe associations with loci associ-
ated with GDM elsewhere including variants in the
CDKAL1 and MTNR1B loci, which have been reported
to be associated with GDM in South Korea [19]. A
sensitivity analysis using controls that had no GDM
diagnosis using either criterion revealed the nominal as-
sociation of variants in SLC30A8, KCNJ11 and ADCY5.
These largely negative findings could be attributed to
population-based differences. Previous studies have indi-
cated differences in anthropometry between Indian and
European populations, with the former manifesting a
“thin-fat” phenotype [36]. Subsequently, it is possible
that since most T2D loci were identified in European
ancestry cohorts, the negative findings could reflect
differences in tagging SNPs due to differences haplo-
types between populations. On the other hand, the
underlying etiology of GDM could also be different gen-
etically. While the study population is the largest GDM
study till date, this might lack sufficient power to detect
genome-wide significance levels of association with an
unstable phenotype. The effect sizes of previously re-
ported T2D loci were low, generally under odds ratios of
1.2, therefore the study was not sufficiently powered to
demonstrate association of SNPs with such low effect
sizes. Alternately, considering the lack of consensus for
GDM diagnosis criteria worldwide, it is plausible that
this could be due to different thresholds that might
apply for the Indian population.
Notably, T2D risk variants in the CRY2 (WHO1999),
CENTD2 (WHO2013) and the ADCY5 (WHO2013)
genes were here protective for GDM. CRY2 encodes for
the cryptochrome protein involved in the regulation of
the circadian clock. Risk allele carriers of the rs11708067
SNP in ADCY5 has previously been shown to reduce
ADCY5 expression in pancreatic beta cells and import-
ant for coupling glucose to insulin secretion in human
islets [37]. It has been previously shown that T2D risk
alleles show extreme directional differentiation across
various populations, with T2D risk alleles decreasing in
frequency along human migration into East Asia [38].
Such flip-flops of risk alleles may be explained by popu-
lation differences, possibly due to genetics or environ-
ment. Alternately, such “flip-flop” associations have also
been attributed to multi-locus effects as shown from
Table 6 Association of selected loci with insulin secretion (HOMA2-B)
SNP EA Chr Gene/nearest gene Location Beta SE p-value N
rs340874 C 1 PROX1 intergenic 0.009 0.011 0.388 3395
rs560887 C 2 G6PC2/ABCB11 intron −0.004 0.016 0.818 3578
rs11708067 A 3 ADCY5 intron −0.024 0.012 0.053 3556
rs11920090 T 3 SLC2A2 intron −0.014 0.015 0.361 3301
rs4607517 A 7 GCK intergenic 0.007 0.012 0.571 3372
rs2191349 T 7 DGKB/TMEM195 intergenic −0.008 0.011 0.480 3575
rs7034200 A 9 GLIS3 intron 0.002 0.016 0.922 3576
rs10885122 G 10 ADRA2A intergenic −0.006 0.010 0.546 3545
rs7944584 A 11 MADD intron −0.021 0.013 0.116 3372
rs7903146 T 10 TCF7L2 Intronic/promoter 0.003 0.011 0.798 3240
rs10830963 G 11 MTNR1B intron −0.007 0.011 0.473 3398
rs174550 T 11 FADS1 intron 0.011 0.014 0.435 3248
rs7756992 G 6 CDKAL1 intron 0.011 0.014 0.446 3576
rs11071657 A 15 FAM148B intergenic −0.023 0.011 0.044 3568
significant p values where p < 0.05 are indicated in bold
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theoretical modeling studies demonstrating that the
direction of allelic effect may flip when tested allele is in-
versely correlated with another risk allele at another
locus, or positively correlated with a protective allele at
another locus [39].
A HWE threshold of < 0.001 in unaffected individuals
based in either criteria was set as a cut-off; SNPs show-
ing significant deviations from HWE should be inter-
preted with caution, since these could be indicative of
population substructures, inbreeding or selection. The
current study only comprises genotyping data from can-
didate SNPs which do not provide sufficient coverage of
the genome to detail population stratification or in-
breeding. HWE could also be indicative of actual associ-
ation. A serious problem in the study of the genetics of
GDM is the implementation of different criteria, since
some women could be classified as controls based on
different criteria. For SNP rs5219 in KCNJ11 (HWE p =
0.004, WHO1999; HWE p = 0.01, WHO2013) and
rs11605924 in CRY2 (HWE p = 0.007 WHO1999 and
HWE p = 0.06, WHO2013), HWE values were nominally
significant for the same criteria where an association
was observed; these findings need to be replicated in in-
dependent cohorts.
Of 6 loci previously associated with insulin resistance,
here 3 also showed an association with HOMA2-IR and
a trend towards significance for GDM2013 but not
GDM1999 including SNPs rs7607980 in the COBLL1
gene [40], rs13389219 near GRB14 and rs10423928 in
the GIPR gene indicating that some of the genetic basis
seem to be driven by previously reported insulin resist-
ance loci. Similarly, a GRS with the 3 variants with the
lowest p-values for insulin secretion associated with
insulin secretion but not GDM2013 or GDM1999.
Taken together, the results demonstrate that GDM in
women from Punjab in Northern India shows a genetic
component, partially shared with GDM in other parts of
the world, and seems to be driven by both insulin resist-
ance and secretion. However, the direction of the effect
can differ; some T2D risk variants were indicative of be-
ing protective for GDM in these Indian women.
Conclusions
GDM in women from Punjab in Northern India shows a
genetic component shared with T2D. This genetic basis
is seemingly driven by a complex interplay between in-
sulin secretion and sensitivity during pregnancy and is at
least partly shared with GDM in other parts of the
world. Interestingly some of the T2D risk variants in
ADCY5 and CRY2 were protective against GDM. Most
of the previous T2D loci discovered in European studies
did not associate with GDM in North India. Interestingly
some T2D risk variants were in fact indicative of being
protective for GDM in these Indian women. This could
be attributed to different genetic etiology or differences
in the LD structure between populations in which the
associated SNPs were identified and Northern Indian
women. GWAS or whole genome sequencing will be
interesting to further unravel the genetic basis of GDM
in India.
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